388 related articles for article (PubMed ID: 25260964)
1. Long-term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease.
Haflidadottir S; Jonasson JG; Norland H; Einarsdottir SO; Kleiner DE; Lund SH; Björnsson ES
BMC Gastroenterol; 2014 Sep; 14():166. PubMed ID: 25260964
[TBL] [Abstract][Full Text] [Related]
2. Causes of Mortality in Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcohol Related Fatty Liver Disease (AFLD).
Johnston MP; Patel J; Byrne CD
Curr Pharm Des; 2020; 26(10):1079-1092. PubMed ID: 32003662
[TBL] [Abstract][Full Text] [Related]
3. Alcoholic and Nonalcoholic Fatty Liver Disease and Liver-Related Mortality: A Cohort Study.
Chang Y; Cho YK; Cho J; Jung HS; Yun KE; Ahn J; Sohn CI; Shin H; Ryu S
Am J Gastroenterol; 2019 Apr; 114(4):620-629. PubMed ID: 30694866
[TBL] [Abstract][Full Text] [Related]
4. Final results of a long-term, clinical follow-up in fatty liver patients.
Dam-Larsen S; Becker U; Franzmann MB; Larsen K; Christoffersen P; Bendtsen F
Scand J Gastroenterol; 2009; 44(10):1236-43. PubMed ID: 19670076
[TBL] [Abstract][Full Text] [Related]
5. Association of Cardiovascular Risk Factors and Metabolic Syndrome with non-alcoholic and alcoholic fatty liver disease: a retrospective analysis.
Han AL
BMC Endocr Disord; 2021 May; 21(1):91. PubMed ID: 33933056
[TBL] [Abstract][Full Text] [Related]
6. Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification: evidence from the Kangbuk Samsung Health Study.
Chang Y; Ryu S; Sung KC; Cho YK; Sung E; Kim HN; Jung HS; Yun KE; Ahn J; Shin H; Wild SH; Byrne CD
Gut; 2019 Sep; 68(9):1667-1675. PubMed ID: 30472683
[TBL] [Abstract][Full Text] [Related]
7. Contribution of Alcoholic and Nonalcoholic Fatty Liver Disease to the Burden of Liver-Related Morbidity and Mortality.
Younossi Z; Henry L
Gastroenterology; 2016 Jun; 150(8):1778-85. PubMed ID: 26980624
[TBL] [Abstract][Full Text] [Related]
8. Alcoholic and Nonalcoholic Fatty Liver Disease and Incident Hospitalization for Liver and Cardiovascular Diseases.
Chang Y; Cho J; Cho YK; Cho A; Hong YS; Zhao D; Ahn J; Sohn CI; Shin H; Guallar E; Ryu S
Clin Gastroenterol Hepatol; 2020 Jan; 18(1):205-215.e7. PubMed ID: 31085337
[TBL] [Abstract][Full Text] [Related]
9. NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients.
Treeprasertsuk S; Björnsson E; Enders F; Suwanwalaikorn S; Lindor KD
World J Gastroenterol; 2013 Feb; 19(8):1219-29. PubMed ID: 23482703
[TBL] [Abstract][Full Text] [Related]
10. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M
Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831
[TBL] [Abstract][Full Text] [Related]
11. Increased risk of cirrhosis and hepatocellular cancer during long-term follow-up of patients with biopsy-proven NAFLD.
Önnerhag K; Nilsson PM; Lindgren S
Scand J Gastroenterol; 2014 Sep; 49(9):1111-8. PubMed ID: 24990583
[TBL] [Abstract][Full Text] [Related]
12. Long-term, clinical follow-up in fatty liver patients.
Bendtsen F; Dam-Larsen S
Dig Dis; 2010; 28(6):709-14. PubMed ID: 21525754
[TBL] [Abstract][Full Text] [Related]
13. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.
Ekstedt M; Hagström H; Nasr P; Fredrikson M; Stål P; Kechagias S; Hultcrantz R
Hepatology; 2015 May; 61(5):1547-54. PubMed ID: 25125077
[TBL] [Abstract][Full Text] [Related]
14. Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD).
Önnerhag K; Hartman H; Nilsson PM; Lindgren S
Scand J Gastroenterol; 2019 Mar; 54(3):328-334. PubMed ID: 30907181
[No Abstract] [Full Text] [Related]
15. Non-alcoholic fatty liver disease (NAFLD) fibrosis score predicts 6.6-year overall mortality of Chinese patients with NAFLD.
Xun YH; Guo JC; Lou GQ; Jiang YM; Zhuang ZJ; Zhu MF; Luo Y; Ma XJ; Liu J; Bian DX; Shi JP
Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):643-9. PubMed ID: 24837195
[TBL] [Abstract][Full Text] [Related]
16. Alcoholic fatty liver disease elevates estimated coronary heart disease risk to levels comparable with those of nonalcoholic fatty liver disease in the Korean population: a cross-sectional study.
Kim HJ; Kim JH; Choe WH; Kwon SY; Lee CH
Clin Mol Hepatol; 2014 Jun; 20(2):154-61. PubMed ID: 25032181
[TBL] [Abstract][Full Text] [Related]
17. Presence of alcoholic steatohepatitis, but no selective histological feature, indicates an increased risk of cirrhosis and premature death.
Semb S; Neermark S; Dam-Larsen S; Franzmann MB; Albrectsen J; Kallemose T; Becker U; Bendtsen F
Scand J Gastroenterol; 2016 Nov; 51(11):1367-74. PubMed ID: 27381376
[TBL] [Abstract][Full Text] [Related]
18. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.
Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
J Hepatol; 2017 Dec; 67(6):1265-1273. PubMed ID: 28803953
[TBL] [Abstract][Full Text] [Related]
19. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease.
Bertot LC; Jeffrey GP; de Boer B; MacQuillan G; Garas G; Chin J; Huang Y; Adams LA
Liver Int; 2018 Oct; 38(10):1793-1802. PubMed ID: 29575516
[TBL] [Abstract][Full Text] [Related]
20. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort.
Simon TG; Roelstraete B; Khalili H; Hagström H; Ludvigsson JF
Gut; 2021 Jul; 70(7):1375-1382. PubMed ID: 33037056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
